LIFEVANTAGE CORP Cash and Cash Equivalents, Period Increase (Decrease)
LIFEVANTAGE CORP (LFVN) reported Cash and Cash Equivalents, Period Increase (Decrease) of $2.34 million for the 6-month period ending 2018-12-31, per its 10-Q filed 2019-02-04.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-02-04
- LIFEVANTAGE CORP cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was $1.87M, a 268.77% increase year-over-year.
- LIFEVANTAGE CORP cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was $471.00K, a 43.25% decline year-over-year.
- LIFEVANTAGE CORP cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was $2.70M, a 19.68% increase year-over-year.
- LIFEVANTAGE CORP cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $1.16M.
- LIFEVANTAGE CORP cash and cash equivalents, period increase (decrease) for fiscal 2018 was $5.19M, a 45.29% increase from fiscal 2017.
- LIFEVANTAGE CORP cash and cash equivalents, period increase (decrease) for fiscal 2017 was $3.58M.
- LIFEVANTAGE CORP cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$6.02M.
- LIFEVANTAGE CORP cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$6.48M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-12-31 | $1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-04 | $2.34M 10-Q · filed 2019-02-04 | $5.04M derived: sum of 3 quarters · filed 2019-02-04 | $6.20M derived: sum of 4 quarters · filed 2019-02-04 | ||||
| 2018-09-30 | $471.00K 10-Q · filed 2018-11-01 | $3.17M derived: sum of 2 quarters · filed 2018-11-01 | $4.33M derived: sum of 3 quarters · filed 2018-11-01 | $4.83M derived: sum of 4 quarters · filed 2019-02-04 | ||||
| 2018-06-30 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-15 | $3.86M derived: sum of 2 quarters · filed 2018-08-15 | $4.36M derived: sum of 3 quarters · filed 2019-02-04 | $5.19M 10-K · filed 2018-08-15 | ||||
| 2018-03-31 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-09 | $1.66M derived: sum of 2 quarters · filed 2019-02-04 | $2.49M 10-Q · filed 2018-05-09 | $4.75M derived: sum of 4 quarters · filed 2019-02-04 | ||||
| 2017-12-31 | $506.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-04 | $1.34M 10-Q · filed 2019-02-04 | $3.59M derived: sum of 3 quarters · filed 2019-02-04 | $1.06M derived: sum of 4 quarters · filed 2019-02-04 | ||||
| 2017-09-30 | $830.00K 10-Q · filed 2018-11-01 | $3.09M derived: sum of 2 quarters · filed 2018-11-01 | $557.00K derived: sum of 3 quarters · filed 2018-11-01 | $2.06M derived: sum of 4 quarters · filed 2018-11-01 | ||||
| 2017-06-30 | $2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-15 | -$273.00K derived: sum of 2 quarters · filed 2018-08-15 | $1.23M derived: sum of 3 quarters · filed 2018-08-15 | $3.58M 10-K · filed 2018-08-15 | ||||
| 2017-03-31 | -$2.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-09 | -$1.02M derived: sum of 2 quarters · filed 2018-05-09 | $1.32M 10-Q · filed 2018-05-09 | $708.00K derived: sum of 4 quarters · filed 2018-08-15 | ||||
| 2016-12-31 | $1.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-07 | $3.85M 10-Q · filed 2018-02-07 | $3.24M derived: sum of 3 quarters · filed 2018-08-15 | -$4.09M derived: sum of 4 quarters · filed 2018-08-15 | ||||
| 2016-09-30 | $2.34M 10-Q · filed 2017-11-08 | $1.73M derived: sum of 2 quarters · filed 2018-08-15 | -$5.59M derived: sum of 3 quarters · filed 2018-08-15 | -$3.46M derived: sum of 4 quarters · filed 2018-08-15 | ||||
| 2016-06-30 | -$611.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-15 | -$7.94M derived: sum of 2 quarters · filed 2018-08-15 | -$5.80M derived: sum of 3 quarters · filed 2018-08-15 | -$6.02M 10-K · filed 2018-08-15 | ||||
| 2016-03-31 | -$7.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-10 | -$5.19M derived: sum of 2 quarters · filed 2017-05-10 | -$5.41M 10-Q · filed 2017-05-10 | -$6.86M derived: sum of 4 quarters · filed 2017-09-07 | ||||
| 2015-12-31 | $2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-08 | $1.91M 10-Q · filed 2017-02-08 | $466.00K derived: sum of 3 quarters · filed 2017-09-07 | -$2.83M derived: sum of 4 quarters · filed 2017-09-07 | ||||
| 2015-09-30 | -$219.00K 10-Q · filed 2016-12-12 | -$1.67M derived: sum of 2 quarters · filed 2017-09-07 | -$4.96M derived: sum of 3 quarters · filed 2017-09-07 | -$8.45M derived: sum of 4 quarters · filed 2017-09-07 | ||||
| 2015-06-30 | -$1.45M derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-09-07 | -$4.74M derived: sum of 2 quarters · filed 2017-09-07 | -$8.23M derived: sum of 3 quarters · filed 2017-09-07 | -$6.48M 10-K · filed 2017-09-07 | ||||
| 2015-03-31 | -$3.29M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2016-07-19 | -$6.78M derived: sum of 2 quarters · filed 2016-07-19 | -$5.03M 10-Q/A · filed 2016-07-19 | -$20.33M derived: sum of 4 quarters · filed 2016-12-12 | ||||
| 2014-12-31 | -$3.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-09 | -$1.74M 10-Q · filed 2016-02-09 | -$17.03M derived: sum of 3 quarters · filed 2016-12-12 | -$15.81M derived: sum of 4 quarters · filed 2016-12-12 | ||||
| 2014-09-30 | $1.75M 10-Q · filed 2015-11-04 | -$13.55M derived: sum of 2 quarters · filed 2016-12-12 | -$12.32M derived: sum of 3 quarters · filed 2016-12-12 | -$5.82M derived: sum of 4 quarters · filed 2016-12-12 | ||||
| 2014-06-30 | -$15.29M derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-12 | -$14.07M derived: sum of 2 quarters · filed 2016-12-12 | -$7.57M derived: sum of 3 quarters · filed 2016-12-12 | -$5.91M 10-K · filed 2016-12-12 | ||||
| 2014-03-31 | $1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-06 | $7.72M derived: sum of 2 quarters · filed 2015-05-06 | $9.38M 10-Q · filed 2015-05-06 | $8.44M derived: sum of 4 quarters · filed 2015-09-01 | ||||
| 2013-12-31 | $6.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-04 | $8.15M 10-Q · filed 2015-02-04 | $7.21M derived: sum of 3 quarters · filed 2015-09-01 | $5.99M derived: sum of 4 quarters · filed 2015-09-01 | ||||
| 2013-09-30 | $1.66M 10-Q · filed 2014-11-06 | $718.00K derived: sum of 2 quarters · filed 2015-09-01 | -$509.00K derived: sum of 3 quarters · filed 2015-09-01 | $2.78M derived: sum of 4 quarters · filed 2015-09-01 | ||||
| 2013-06-30 | -$940.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-01 | -$2.17M derived: sum of 2 quarters · filed 2015-09-01 | $1.12M derived: sum of 3 quarters · filed 2015-09-01 | $1.65M 10-K · filed 2015-09-01 | ||||
| 2013-03-31 | -$1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-06 | $2.06M derived: sum of 2 quarters · filed 2014-05-06 | $2.59M 10-Q · filed 2014-05-06 | $10.34M derived: sum of 4 quarters · filed 2014-09-10 | ||||
| 2012-12-31 | $3.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-02-06 | $3.82M 10-Q · filed 2014-02-06 | $11.57M derived: sum of 3 quarters · filed 2014-09-10 | $15.01M derived: sum of 4 quarters · filed 2014-09-10 | ||||
| 2012-09-30 | $530.00K 10-Q · filed 2013-11-07 | $8.28M derived: sum of 2 quarters · filed 2014-09-10 | $11.72M derived: sum of 3 quarters · filed 2014-09-10 | $15.74M derived: sum of 4 quarters · filed 2014-09-10 | ||||
| 2012-06-30 | $7.75M derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-10 | $11.19M derived: sum of 2 quarters · filed 2014-09-10 | $15.21M derived: sum of 3 quarters · filed 2014-09-10 | $18.28M 10-K · filed 2014-09-10 | $18.28M 10-K · filed 2012-09-10 | |||
| 2012-03-31 | $3.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-05-09 | $7.46M derived: sum of 2 quarters · filed 2013-05-09 | $10.53M 10-Q · filed 2013-05-09 | $10.53M 10-Q · filed 2012-05-15 | $12.80M derived: sum of 4 quarters · filed 2013-09-12 | |||
| 2011-12-31 | $4.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-02-07 | $7.09M 10-Q · filed 2013-02-07 | $7.09M 10-Q · filed 2012-02-14 | $9.37M derived: sum of 3 quarters · filed 2013-09-12 | $10.72M derived: sum of 4 quarters · filed 2013-09-12 | |||
| 2011-09-30 | $3.07M 10-Q · filed 2012-11-08 | $3.07M 10-Q · filed 2011-11-14 | $5.34M derived: sum of 2 quarters · filed 2013-09-12 | $6.70M derived: sum of 3 quarters · filed 2013-09-12 | $7.18M derived: sum of 4 quarters · filed 2013-09-12 | |||
| 2011-06-30 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2013-09-12 | $3.63M derived: sum of 2 quarters · filed 2013-09-12 | $4.11M derived: sum of 3 quarters · filed 2013-09-12 | $4.73M 10-K · filed 2013-09-12 | $4.73M 10-K · filed 2012-09-10 | |||
| 2011-03-31 | $1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-05-15 | $1.84M derived: sum of 2 quarters · filed 2012-05-15 | $2.46M 10-Q · filed 2012-05-15 | |||||
| 2010-12-31 | $479.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-02-14 | $1.10M 10-Q · filed 2012-02-14 | ||||||
| 2010-09-30 | $619.38K 10-Q · filed 2011-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |